CClinicalTrials.gg
CompletedNCT04665011Updated Mar 16, 2021

Validation of Indicor Photoplethysmography (PPG) Valsalva Pulse Response vs Non-invasive Blood Pressure

An observational study in Heart Failure, sponsored by Vixiar Medical, Inc.. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-03-16.

Sponsored by Vixiar Medical, Inc. · Observational

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
121
Ages
18 Years and older
Sex
All
01

Study summary

This study designed is compare the pulse response to the Valsalva maneuver between a photoplethysmography sensor (PPG) and non-invasive blood pressure sensor for the purpose of validating the PPG methodology in deriving a value for the Valsalva pulse response. The aim is to show that the PPG method captures the same phase responses as the blood pressure monitor and the primary outcome is the correlation between pulse amplitude ratios for the pulse at the end of the Valsalva to an average baseline pulse.

Read the detailed description

With both a photoplethysmography (PPG; Indicor, Vixiar Medical,. Baltimore, MD) and non-invasive blood pressure (Caretaker, Caretaker Medical, Charlottesville, VA) sensors in place on the index and middle fingers, respectively, each patient will be asked to perform three mild, 10-sec Valsalva maneuvers with at least 45 seconds between. Pulse recordings will be collected from each device to compare phases of the Valsalva pulse response including pulse amplitude changes and baseline movement. The primary outcome is the correlation between pulse amplitude ratios for the pulse at the end of the Valsalva to an average baseline pulse.

02

Conditions studied

  • Heart Failure

Browse trials for

03

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

The study sample has a focus on heart failure patients as this is a clinical target population for the clinical use of the Indicor. However, non-heart failure subjects may be needed to ensure that a range of normal outcome values are included in the analysis. Therefore, at least 70% of the enrollment is intended to be derived from a cardiology practice office, and up to 30% of the enrollment may be non-patient participants.

Inclusion criteria

  • Clinically stable adults, including heart failure patients visiting an outpatient clinic

Exclusion criteria

Exclusion Criteria:

  • Atrial flutter or atrial fibrillation with an irregular ventricular response
  • Significant atrial or ventricular ectopy
  • History of paradoxical emboli
  • Hypertrophic obstructive cardiomyopathy
  • Known intracardiac shunt
  • Known severe aortic valve stenosis
  • Known severe mitral valve stenosis
  • History of embolic CVA
  • Myocardial infarction within one week of intended Indicor testing
  • Uncontrolled hypertension (systolic BP >160mmHg or diastolic BP>100mmHg)
  • Hypotension (systolic BP \<90mmHg)
  • Symptomatic bradycardia
  • Known cholesterol emboli
  • Poor left ventricular function with left ventricular thrombus
  • Unstable angina
  • Significant aortic valvular disease
  • Patients weighing less than 40kg
04

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
121 participants (actual)
Patient registry
No

Groups and cohorts

  • Clinically stable adults, including heart failure patients visiting an outpatient clinic

    Observational to compare simultaneous pulse tracings from PPG and non-invasive blood pressure monitors in capturing the pulse responses to a Valsalva maneuver.

    Device: Indicor · Device: Caretaker

Interventions

  • DeviceIndicor

    A simple, non-invasive tool to report pulse response to a Valsalva maneuver

  • DeviceCaretaker

    non-invasive blood pressure monitor

05

What researchers measure

Primary outcomes

  1. pulse amplitude ratio

    The correlation between PPG-based and non-invasive blood pressure pulse amplitude ratio during a Valsalva maneuver.

    Time frame: 5 minutes

Secondary outcomes

  1. Phases of valsalva pulse response

    The agreement between PPG-based and non-invasive blood pressure pulse tracings during a Valsalva maneuver.

    Time frame: 5 minuntes

06

Study locations

1 site
  • Fort Norfolk Cardiology Associates
    Norfolk, Virginia 23510, United States
07

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT04665011
Lead sponsor
Vixiar Medical, Inc.
Responsible party
Sponsor
First posted
Dec 11, 2020
Start date
Dec 14, 2020
Primary completion
Jan 28, 2021
Completion
Jan 28, 2021
Last update
Mar 16, 2021

Study contacts

Keith H. Newby, M.D.
principal investigator · Fort Norfolk Cardiology Associates

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion